Predictive factors of hepatitis B virus DNA negative conversion among patients with chronic hepatitis B during lamivudine therapy
Chen, J.-L.; Wang, L.; Yan, J.; Zhang, L.; Yu, H.; Fan, X.-L.
Zhonghua Shi Yan he Lin Chuang Bing du Xue Za Zhi 21(3): 273-275
2007
ISSN/ISBN: 1003-9279 PMID: 17971944 Document Number: 612580
To study the occurrence and predictive factors of hepatitis B virus DAN negative conversion among patients with chronic hepatitis B and liver cirrhosis during lamivudine therapy. Clinical data of 202 patients with chronic hepatitis B and 55 patients with post-hepatitis B cirrhosis treated with lamivudine therapy were analyzed and PCR as well as mispairing PCR-restricted fragment length polymorphism (RFLP) assay were applied. The data including ALT, AST, total bilirubin (TBIL), albumin, etc. were analyzed by SPSS software. The HBV DNA negative conversion occurred in 87.62%, 95.04%, 86.63%, 82.65%, 75.43%, and 77.27% of the chronic hepatitis B patients and in 94.54%, 98.18%, 81.81%, 74.35%, 73.91%, and 63.63% of liver cirrhosis patients, respectively, after 3, 6, 12, 18, 24, 30 months. The results of log-rank test and Cox proportional hazard model analysis indicated that combination of lamivudine and interferon, high ALT level,low HBV DNA level, and low albumin level at baseline were significantly related to HBV DNA negative conversion. Combination treatment with lamivudine and interferon, high ALT level, low HBV DNA level, and low albumin level at baseline were significant predicting predicting factors for HBV DNA negative conversion in chronic hepatitis B patients.